The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities ...

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...